EGFR and breast carcinoma: The coordinated actions of ERs with EGFR and IGF‐IR affect ECM composition (i.e., syndecan expression), Erk1/2‐dependent signaling, and crucial breast cancer cell properties, including migration and adhesion to fibronectin [36, 37].